trending Market Intelligence /marketintelligence/en/news-insights/trending/AfwYRUYbO6CEftrg6ZmpGg2 content esgSubNav
Discover more about S&P Global’s offerings
In This List

Private equity firm Afinum buys majority stake in Swiss biotech evitria
Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Private equity firm Afinum buys majority stake in Swiss biotech evitria

Private equity firm Afinum Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in Swiss biotechnology company evitria AG.

Evitria provides custom antibodies to pharmaceutical and biotech companies for research purposes.

Afinum Achte Beteiligungsgesellschaft mbH & Co. KG, advised by Afinum Management GmbH, acts as lead investor and majority owner, and jointly invests with SHS V Medtech Investments GmbH & Co. KG and management into evitria.